Show simple item record

dc.contributor.authorEniu, Dan Tudor
dc.contributor.authorNasioulas, George
dc.contributor.authorTansan, Sualp
dc.contributor.authorKaban, Kerim
dc.contributor.authorChiorean, Angelica
dc.contributor.authorAgiannitopoulos, Konstantinos
dc.contributor.authorPepe, Georgia
dc.contributor.authorPapadopoulou, Eirini
dc.contributor.authorTsaousis, Georgios N.
dc.contributor.authorKampouri, Stavroula
dc.contributor.authorMaravelaki, Sonia
dc.contributor.authorFassas, Athanassios
dc.contributor.authorChristodoulou, Christos
dc.contributor.authorIosifidou, Rodoniki
dc.contributor.authorKarageorgopoulou, Sofia
dc.contributor.authorMarkopoulos, Christos
dc.contributor.authorNatsiopoulos, Ioannis
dc.contributor.authorPapazisis, Konstantinos
dc.contributor.authorVasilaki-Antonatou, Maria
dc.contributor.authorVenizelos, Vassileios
dc.contributor.authorOzmen, Vahit
dc.date.accessioned2021-12-10T11:31:43Z
dc.date.available2021-12-10T11:31:43Z
dc.date.issued2021
dc.identifier.citationAgiannitopoulos K., Pepe G., Papadopoulou E., Tsaousis G. N. , Kampouri S., Maravelaki S., Fassas A., Christodoulou C., Iosifidou R., Karageorgopoulou S., et al., "Clinical Utility of Functional RNA Analysis for the Reclassification of Splicing Gene Variants in Hereditary Cancer", CANCER GENOMICS & PROTEOMICS, cilt.18, sa.3, ss.285-294, 2021
dc.identifier.issn1109-6535
dc.identifier.othervv_1032021
dc.identifier.otherav_83b05083-f3f9-4a59-80ce-fe02d5d03a77
dc.identifier.urihttp://hdl.handle.net/20.500.12627/172069
dc.identifier.urihttps://doi.org/10.21873/cgp.20259
dc.description.abstractBackground: Classification of splicing variants (SVs) in genes associated with hereditary cancer is often challenging. The aim of this study was to investigate the occurrence of SVs in hereditary cancer genes and the clinical utility of RNA analysis. Material and Methods: 1518 individuals were tested for cancer predisposition, using a Next Generation Sequencing ( NGS) panel of 36 genes. Splicing variant analysis was performed using RT-PCR and Sanger Sequencing. Results: In total, 34 different SVs were identified, 53% of which were classified as pathogenic or likely pathogenic. The remaining 16 variants were initially classified as Variant of Uncertain Significance (VUS). RNA analysis was performed for 3 novel variants. Conclusion: The RNA analysis assisted in the reclassification of 20% of splicing variants from VUS to pathogenic. RNA analysis is essential in the case of uncharacterized splicing variants, for proper classification and personalized management of these patients.
dc.language.isoeng
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectTıbbi Genetik
dc.subjectYaşam Bilimleri
dc.subjectMoleküler Biyoloji ve Genetik
dc.subjectTemel Bilimler
dc.subjectGenetics
dc.subjectMolecular Biology
dc.subjectGenetics (clinical)
dc.subjectOncology
dc.subjectLife Sciences
dc.subjectHealth Sciences
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectMoleküler Biyoloji ve Genetik
dc.subjectGENETİK VE HAYAT
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.titleClinical Utility of Functional RNA Analysis for the Reclassification of Splicing Gene Variants in Hereditary Cancer
dc.typeMakale
dc.relation.journalCANCER GENOMICS & PROTEOMICS
dc.contributor.departmentGenekor Med SA , ,
dc.identifier.volume18
dc.identifier.issue3
dc.identifier.startpage285
dc.identifier.endpage294
dc.contributor.firstauthorID2634654


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record